SS
CELZ icon

Steve Schonfeld’s Creative Medical Technology CELZ Stock Holding History

Steve Schonfeld’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,160
Closed -$84K – 2584
2022
Q1 		$84K Buy
+2,160
New +$48.1K ﹤0.01% 2270

Other funds holding CELZ

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Steve Schonfeld's CELZ Position: Q2 2022 in Review

Steve Schonfeld sold out of Creative Medical Technology (CELZ) in Q2 2022, closing a stake of 2,160 shares — an estimated $84K sold.

Steve Schonfeld first reported a position in CELZ in Q1 2022 and held it in 1 quarter. The position peaked at $84K in Q1 2022. 14 funds tracked by Wall St. Rank hold CELZ as of Q2 2022.

  • Steve Schonfeld reported no remaining Creative Medical Technology position as of Q2 2022 after selling out during the quarter.
  • Steve Schonfeld sold 2,160 Creative Medical Technology shares in Q2 2022, an estimated $84K.
  • Steve Schonfeld first reported a position in Creative Medical Technology in Q1 2022 and held it in 1 quarter.
  • Steve Schonfeld's Creative Medical Technology position peaked at $84K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.